Eric Dobmeier, Chinook Therapeutics CEO
April 11, 2023 10:46 AM EDTUpdated April 13, 08:48 AM
R&D

Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

Paul Schloesser

Associate Editor

Chi­nook Ther­a­peu­tics said it tem­porar­i­ly halt­ed dos­ing par­tic­i­pants in the Phase I tri­al of its treat­ment for an ul­tra-rare ge­net­ic kid­ney dis­ease af­ter one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times